ProCE Banner Activity

STOMP Phase I/II Trial: Selinexor/Pomalidomide/Dexamethasone in R/R MM After ≥ 2 Previous Therapies

Slideset Download
Conference Coverage
All-oral regimen of selinexor/pomalidomide/low-dose dexamethasone appears to be highly active and have a manageable safety profile in patients with R/R MM after ≥ 2 previous therapies.

Released: December 10, 2020

Expiration: December 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology